<?xml version="1.0" encoding="UTF-8"?>
<p>Baricitinib is an orally administered, JAK antagonist monoclonal antibody used routinely for the treatment of rheumatoid arthritis [
 <xref rid="B204-ijms-21-05559" ref-type="bibr">204</xref>]. Although JAK blockers are considered as potential therapeutic agents in inflammatory storms, several researchers have reported that baricitinib is unlikely to be useful for COVID-19 [
 <xref rid="B205-ijms-21-05559" ref-type="bibr">205</xref>] due to its well-known side effects, including lymphocytopenia and neutropenia, and therefore the risk of viral reactivation [
 <xref rid="B205-ijms-21-05559" ref-type="bibr">205</xref>].
</p>
